search
Back to results

Initiation of ARNi and SGLT2i in Patients With HFrEF (INITIATE)

Primary Purpose

Heart Failure With Reduced Ejection Fraction

Status
Recruiting
Phase
Phase 4
Locations
Portugal
Study Type
Interventional
Intervention
Sacubitril-valsartan
SGLT2 inhibitor
Sponsored by
Universidade do Porto
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Heart Failure With Reduced Ejection Fraction

Eligibility Criteria

18 Years - undefined (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria: Age ≥ 18 years Heart failure symptoms (NYHA II, III or IV) Left ventricle ejection fraction ≤ 49% (assessed by transthoracic echocardiogram) Glomerular filtration rate ≥ 25 ml/min/1.73m2 (CKD-EPI formula) Serum potassium (K+) ≤ 5.4 mmol/L Systolic blood pressure ≥ 100 mmHg Not treated with ARNi nor with SGLT2i within the previous month (30 days before inclusion, except if initiated 5 days before randomization) If female, she must not be a woman of childbearing potential. That is, she must be: Surgically sterilized (e.g., underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy) Clinically diagnosed infertile In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause If female patient of childbearing potential, she must have a negative serum pregnancy test at Visit 1 (Day 0) and must agree to consistently and correctly use (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception: Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject) Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) Intrauterine device Intrauterine hormone-releasing system Bilateral tubal occlusion Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner Exclusion Criteria: Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) Participation in another clinical study with an investigational product during the last month Unwilling to sign inform consent Patients with a known hypersensitivity or intolerance to ARNi or SGLT2i or any of the excipients of the products Hospitalization due to non-cardiovascular causes, surgical procedure, coronary, cerebral or peripheral vascular events or sepsis in the prior month Cancer (life limiting with an estimated life expectancy of less than 2 years based on investigator's judgement) Previously confirmed cardiac amyloidosis History of angioedema Implantable cardioverter-defibrillators or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device in the 3 months following screening Female patients currently pregnant (confirmed by a positive pregnancy test) or intent to become pregnant or breast feeding Severe valvulopathy according to the echocardiogram report Previous history of ketoacidosis due to SGLT2i

Sites / Locations

  • Centro Hospitalar Universitário de Santo AntónioRecruiting
  • Centro Hospitalar Universitário São JoãoRecruiting
  • Faculty of Medicine (FMUP)Recruiting
  • Centro Hospitalar Vila Nova de Gaia/EspinhoRecruiting
  • Unidade Local de Saúde de Matosinhos - Hospital Pedro HispanoRecruiting

Arms of the Study

Arm 1

Arm 2

Arm Type

Active Comparator

Active Comparator

Arm Label

Simultaneous initiation

Sequential initiation

Arm Description

ARNi (initial dose 24/26mg b.i.d. or 49/51mg b.i.d. titrated to 97/103mg b.i.d. preferably in the first 3-6 weeks, up to 3 months of follow-up) and SGLT2i (10mg q.d.) on the same day or within ± 5 days.

Initial (at randomization day) SGLT2i prescription (either empagliflozin or dapagliflozin, 10 mg q.d.) followed by an ARNi initiated between weeks 4 and 12 after randomization (sacubitril/valsartan at an initial dose of 24/26mg b.i.d. or 49/51mg b.i.d., and titrated to 97/103mg b.i.d. if tolerated, according to assistant physician decision)

Outcomes

Primary Outcome Measures

Composite outcome (time-to-first event' occurrence during the 6 months of follow-up):
Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion); Hyperkalaemia (serum potassium >6.0 mmol/L); Hypokalemia (serum potassium <3.0 mmol/L); eGFR drop ≥50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis; Increase in diuretic dose due to worsening heart failure; Use of intravenous diuretics for worsening heart failure; Heart failure hospitalization; Death from cardiovascular causes.

Secondary Outcome Measures

Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion)
Time to event' occurrence during the 6 months of follow-up
Hyperkalaemia (serum potassium >6.0 mmol/L)
Time to event' occurrence during the 6 months of follow-up
Hypokalemia (serum potassium <3.0 mmol/L)
Time to event' occurrence during the 6 months of follow-up
eGFR drop ≥50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis
Time to event' occurrence during the 6 months of follow-up
Increase in diuretic dose due to worsening heart failure
Time to event' occurrence during the 6 months of follow-up
Use of intravenous diuretics for worsening heart failure
Time to event' occurrence during the 6 months of follow-up
Heart failure hospitalization
Time to event' occurrence during the 6 months of follow-up
Death from cardiovascular causes
Time to event' occurrence during the 6 months of follow-up
NT-pro BNP or BNP (log)
Concentration measured in blood samples
High sensitivity C-reactive protein
Concentration measured in blood samples
Atrial fibrillation/flutter
Electrocardiogram (yes/no)
Systolic and diastolic blood pressure
Measure in the clinical appointments
High sensitivity Troponin
Concentration measured in blood samples
Left atrial volume
Transthoracic echocardiogram
Left ventricular systolic volume
Transthoracic echocardiogram
Left ventricular diastolic volume
Transthoracic echocardiogram
LV mass
Transthoracic echocardiogram
LV ejection fraction
Transthoracic echocardiogram
Pulmonary artery systolic pressure
Transthoracic echocardiogram
Serum sodium
Concentration measured in blood samples
Serum potassium
Concentration measured in blood samples
Serum creatinine
Concentration measured in blood samples
Glomerular filtration rate (eGFR)
Calculated from the serum creatinine using the 2021 CKD-EPI creatinine-based formula
Urinary sodium
Spot urine sample
Urinary potassium
Spot urine sample
Microalbuminuria
Spot urine sample
Total Cholesterol
Concentration measured in blood samples
LDL Cholesterol
Concentration measured in blood samples
HDL Cholesterol
Concentration measured in blood samples
Triglycerides
Concentration measured in blood samples
Glucose
Measured in blood samples
Glycated hemoglobin (HbA1C)
Concentration measured in blood samples
Uric acid
Concentration measured in blood samples
TSH
Concentration measured in blood samples
Free thyroxin
Concentration measured in blood samples
ALAT
Concentration measured in blood samples
ASAT
Concentration measured in blood samples
Gamma-GT
Concentration measured in blood samples
Alkaline Phosphatase
Concentration measured in blood samples
Total bilirubin
Concentration measured in blood samples
Serum iron
Concentration measured in blood samples
Ferritin
Concentration measured in blood samples
Transferrin saturation
Concentration measured in blood samples
Functional class (NYHA, New York Heart Association)
Assessed by the medical doctors in the clinical appointments (I / II / III / IV)
Quality of life (KCCQ, Kansas City Cardiomyopathy Questionnaire)
HR-QoL assessed by the Kansas City Cardiomyopathy Questionnaire a 12-item instrument. All items are measured on a Likert scale with 5-7 response options. KCCQ scores are scaled from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
Dosage titration of sacubitril/valsartan up to the dose 97/103 mg (b.i.d.) at 3 months
Assessed by the medical doctors in the clinical appointments

Full Information

First Posted
July 14, 2023
Last Updated
October 18, 2023
Sponsor
Universidade do Porto
Collaborators
Faculty of Medicine (FMUP), Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC), Rede de Investigação em Saúde (RISE), Laboratório Associado
search

1. Study Identification

Unique Protocol Identification Number
NCT05989503
Brief Title
Initiation of ARNi and SGLT2i in Patients With HFrEF
Acronym
INITIATE
Official Title
Initiation of Angiotensin Receptor-neprilysin Inhibitor (ARNi) and Sodium-glucose Cotransporter-2 Inhibitors (SGLT2i) in Patients With Heart Failure With Reduced Ejection Fraction (HFrEF): the INITIATE-HFrEF Randomized Open-label Trial
Study Type
Interventional

2. Study Status

Record Verification Date
June 2023
Overall Recruitment Status
Recruiting
Study Start Date
August 4, 2023 (Actual)
Primary Completion Date
November 2024 (Anticipated)
Study Completion Date
February 2025 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Universidade do Porto
Collaborators
Faculty of Medicine (FMUP), Unidade de Investigação e Desenvolvimento Cardiovascular (UnIC), Rede de Investigação em Saúde (RISE), Laboratório Associado

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No

5. Study Description

Brief Summary
Heart failure (HF) is a condition in which the heart does not contract ("pump") or relax well, leading to insufficient perfusion of vital organs. Ankle swelling, fatigue, and breathlessness are some of the features of this syndrome. There are different causes for HF (e.g., infarct and hypertension) and two distinct types: HFpEF - HF with preserved ejection fraction - the heart "pumps" but does not relax well and HFrEF/HFmrEF - HF with reduced or mildly reduced ejection fraction - where the heart does not "pump" properly. Patients with HFrEF experience substantially shorter life expectancies compared with people in the general population of similar age. Compared to the different available therapeutics for HFrEF patients, angiotensin receptor-neprilysin inhibitor (ARNi), sacubitril/valsartan, has shown superiority for improving clinical outcomes. Furthermore, the new recently drug sodium-glucose cotransporter 2 inhibitor (SGLT2i) was proven to reduce mortality and morbidity on top of well-adapted background therapy. This work aims to test the safety of ARNi and SGLT2i initiation by comparing a strategy of simultaneous initiation of ARNi and SGLT2i versus sequential initiation of a SGLT2i first followed by an ARNi.
Detailed Description
Sacubitril/valsartan and SGLT2i reduced HF hospitalizations and mortality in patients with heart failure and a reduced ejection fraction with a rapid onset of action, but the timing of initiation of each drug is uncertain. Clinicians may be reluctant to initiate both therapies simultaneously due to fear of adverse events (e.g., hypotension and worsening renal function) which may delay the initiation of (at least one) of these life-saving therapies. This study aims to fill this gap in knowledge by studying the initiation of sacubitril/valsartan and a SGLT2i simultaneously or in sequence. This study will better inform clinicians on their daily decisions.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Heart Failure With Reduced Ejection Fraction

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 4
Interventional Study Model
Parallel Assignment
Model Description
Pragmatic study to be conducted in real-life routine practice conditions with a two-arm open randomization, to evaluate the efficacy (on surrogate markers) and safety of ARNi and SGLT2i combination in patients with HFrEF/HFmrEF and the doses of ARNi. initiation of ARNi and SGLT2i simultaneously (same day or within ± 5 days); initial SGLT2i initiation followed by ARNi between week 4 and 12 after randomization.
Masking
None (Open Label)
Allocation
Randomized
Enrollment
172 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Simultaneous initiation
Arm Type
Active Comparator
Arm Description
ARNi (initial dose 24/26mg b.i.d. or 49/51mg b.i.d. titrated to 97/103mg b.i.d. preferably in the first 3-6 weeks, up to 3 months of follow-up) and SGLT2i (10mg q.d.) on the same day or within ± 5 days.
Arm Title
Sequential initiation
Arm Type
Active Comparator
Arm Description
Initial (at randomization day) SGLT2i prescription (either empagliflozin or dapagliflozin, 10 mg q.d.) followed by an ARNi initiated between weeks 4 and 12 after randomization (sacubitril/valsartan at an initial dose of 24/26mg b.i.d. or 49/51mg b.i.d., and titrated to 97/103mg b.i.d. if tolerated, according to assistant physician decision)
Intervention Type
Drug
Intervention Name(s)
Sacubitril-valsartan
Intervention Description
Sacubitril-valsartan titration at the discretion of the treating physician
Intervention Type
Drug
Intervention Name(s)
SGLT2 inhibitor
Intervention Description
Either empagliflozin or dapagliflozin 10 mg/day
Primary Outcome Measure Information:
Title
Composite outcome (time-to-first event' occurrence during the 6 months of follow-up):
Description
Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion); Hyperkalaemia (serum potassium >6.0 mmol/L); Hypokalemia (serum potassium <3.0 mmol/L); eGFR drop ≥50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis; Increase in diuretic dose due to worsening heart failure; Use of intravenous diuretics for worsening heart failure; Heart failure hospitalization; Death from cardiovascular causes.
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Secondary Outcome Measure Information:
Title
Symptomatic hypotension (systolic blood pressure <100 mmHg with signs or symptoms compatible with hypoperfusion)
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Hyperkalaemia (serum potassium >6.0 mmol/L)
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Hypokalemia (serum potassium <3.0 mmol/L)
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
eGFR drop ≥50% from baseline or eGFR <15 ml/min/1.73m2 or renal transplant or dialysis
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Increase in diuretic dose due to worsening heart failure
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Use of intravenous diuretics for worsening heart failure
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Heart failure hospitalization
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Death from cardiovascular causes
Description
Time to event' occurrence during the 6 months of follow-up
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
NT-pro BNP or BNP (log)
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
High sensitivity C-reactive protein
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Atrial fibrillation/flutter
Description
Electrocardiogram (yes/no)
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Systolic and diastolic blood pressure
Description
Measure in the clinical appointments
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
High sensitivity Troponin
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Left atrial volume
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Left ventricular systolic volume
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Left ventricular diastolic volume
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
LV mass
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
LV ejection fraction
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Pulmonary artery systolic pressure
Description
Transthoracic echocardiogram
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Serum sodium
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Serum potassium
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Serum creatinine
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Glomerular filtration rate (eGFR)
Description
Calculated from the serum creatinine using the 2021 CKD-EPI creatinine-based formula
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Urinary sodium
Description
Spot urine sample
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Urinary potassium
Description
Spot urine sample
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Microalbuminuria
Description
Spot urine sample
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Total Cholesterol
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
LDL Cholesterol
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
HDL Cholesterol
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Triglycerides
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Glucose
Description
Measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Glycated hemoglobin (HbA1C)
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Uric acid
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
TSH
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
Free thyroxin
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 4 (visit 3 + 90±15 days)
Title
ALAT
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
ASAT
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Gamma-GT
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Alkaline Phosphatase
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Total bilirubin
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Serum iron
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Ferritin
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Transferrin saturation
Description
Concentration measured in blood samples
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Functional class (NYHA, New York Heart Association)
Description
Assessed by the medical doctors in the clinical appointments (I / II / III / IV)
Time Frame
visit 1 (day 0); visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Quality of life (KCCQ, Kansas City Cardiomyopathy Questionnaire)
Description
HR-QoL assessed by the Kansas City Cardiomyopathy Questionnaire a 12-item instrument. All items are measured on a Likert scale with 5-7 response options. KCCQ scores are scaled from 0 to 100 and summarized in 25-point ranges, where scores represent health status as follows: 0 to 24: very poor to poor; 25 to 49: poor to fair; 50 to 74: fair to good; and 75 to 100: good to excellent
Time Frame
visit 1 (day 0); visit 3 (visit 2 + 60 ±15 days); visit 4 (visit 3 + 90±15 days)
Title
Dosage titration of sacubitril/valsartan up to the dose 97/103 mg (b.i.d.) at 3 months
Description
Assessed by the medical doctors in the clinical appointments
Time Frame
visit 2 (day 23 to 37); visit 3 (visit 2 + 60 ±15 days)

10. Eligibility

Sex
All
Minimum Age & Unit of Time
18 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Age ≥ 18 years Heart failure symptoms (NYHA II, III or IV) Left ventricle ejection fraction ≤ 49% (assessed by transthoracic echocardiogram) Glomerular filtration rate ≥ 25 ml/min/1.73m2 (CKD-EPI formula) Serum potassium (K+) ≤ 5.4 mmol/L Systolic blood pressure ≥ 100 mmHg Not treated with ARNi nor with SGLT2i within the previous month (30 days before inclusion, except if initiated 5 days before randomization) If female, she must not be a woman of childbearing potential. That is, she must be: Surgically sterilized (e.g., underwent hysterectomy, bilateral salpingectomy or bilateral oophorectomy) Clinically diagnosed infertile In a post-menopausal state, defined as no menses for 12 months without an alternative medical cause If female patient of childbearing potential, she must have a negative serum pregnancy test at Visit 1 (Day 0) and must agree to consistently and correctly use (from 28 days prior to first study treatment administration until at least 7 days after last study treatment administration) one of the following highly effective methods of contraception: Abstinence of heterosexual intercourse (when this is in line with preferred and usual lifestyle of the subject) Progestogen-only hormonal contraception associated with inhibition of ovulation (oral, injectable, implantable) Combined (estrogen and progestogen containing) hormonal contraception associated with inhibition of ovulation (oral, intravaginal, transdermal) Intrauterine device Intrauterine hormone-releasing system Bilateral tubal occlusion Vasectomized partner, who has received medical assessment of the surgical success, or clinically diagnosed infertile partner Exclusion Criteria: Involvement in the planning and/or conduct of the study (applies to both Investigator staff and/or staff at the study site) Participation in another clinical study with an investigational product during the last month Unwilling to sign inform consent Patients with a known hypersensitivity or intolerance to ARNi or SGLT2i or any of the excipients of the products Hospitalization due to non-cardiovascular causes, surgical procedure, coronary, cerebral or peripheral vascular events or sepsis in the prior month Cancer (life limiting with an estimated life expectancy of less than 2 years based on investigator's judgement) Previously confirmed cardiac amyloidosis History of angioedema Implantable cardioverter-defibrillators or cardiac resynchronization therapy within 3 months prior to screening or if there is an intent to implant either device in the 3 months following screening Female patients currently pregnant (confirmed by a positive pregnancy test) or intent to become pregnant or breast feeding Severe valvulopathy according to the echocardiogram report Previous history of ketoacidosis due to SGLT2i
Central Contact Person:
First Name & Middle Initial & Last Name or Official Title & Degree
João P. Ferreira, PhD
Phone
(+351) 220426820
Email
jpferreira@med.up.pt
First Name & Middle Initial & Last Name or Official Title & Degree
Janete Santos, PhD
Phone
(+351) 225 513 600
Email
investigaclinica@med.up.pt
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
João P. Ferreira, MD, PhD
Organizational Affiliation
Faculty of Medicine (FMUP)
Official's Role
Principal Investigator
Facility Information:
Facility Name
Centro Hospitalar Universitário de Santo António
City
Porto
ZIP/Postal Code
4099-001
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Mário Santos, MD, PhD
Phone
+351 22 207 7500
Email
mariosantos.cardiologia@chporto.min-saude.pt
First Name & Middle Initial & Last Name & Degree
Mário Santos, MD, PhD
Facility Name
Centro Hospitalar Universitário São João
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francisco Vasques-Nóvoa, MD, PhD
Phone
(+351) 225512100
Email
francisco.faria@chsj.min-saude.pt
First Name & Middle Initial & Last Name & Degree
Francisca Saraiva, PhD
Phone
(+351) 225512100
Email
f.saraiva@med.up.pt
First Name & Middle Initial & Last Name & Degree
Francisco Vasques-Nóvoa
Facility Name
Faculty of Medicine (FMUP)
City
Porto
ZIP/Postal Code
4200-319
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Francisca Saraiva, PhD
Phone
(+351) 225512100
Email
f.saraiva@med.up.pt
Facility Name
Centro Hospitalar Vila Nova de Gaia/Espinho
City
Porto
ZIP/Postal Code
4434-502
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Joana Pimenta, MD, PhD
Phone
(+351) 227865100
Email
joana.pimenta@chvng.min-saude.pt
First Name & Middle Initial & Last Name & Degree
Ana C. Oliveira, MSc
Email
crisoliveira@med.up.pt
First Name & Middle Initial & Last Name & Degree
Joana Pimenta, MD, PhD
Facility Name
Unidade Local de Saúde de Matosinhos - Hospital Pedro Hispano
City
Porto
Country
Portugal
Individual Site Status
Recruiting
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Cristina Gavina, MD, PhD
Email
cristina.gavina@ulsm.min-saude.pt
First Name & Middle Initial & Last Name & Degree
Cristina Gavina, MD, PhD

12. IPD Sharing Statement

Learn more about this trial

Initiation of ARNi and SGLT2i in Patients With HFrEF

We'll reach out to this number within 24 hrs